The asthma & allergy friendly® Certification Program Featured Its Certified Products to the Homebuilding Industry’s Leaders and Experts From Across the Globe at the 2020 NAHB International Builders Show and Kitchen & Bath Industry Show
January 28, 2020 12:00 ET
|
Allergy Standards Limited
WASHINGTON, Jan. 28, 2020 (GLOBE NEWSWIRE) -- The asthma & allergy friendly® Certification Program, which is jointly run by Allergy Standards Limited (ASL) and the Asthma and Allergy Foundation...
Houston Methodist (part of Texas Medical Center) to start patient enrollment for Biomerica’s InFoods® Irritable Bowel Syndrome (IBS) diagnostic guided therapy clinical trial
January 07, 2020 08:19 ET
|
Biomerica, Inc.
Texas Medical Center is the largest medical complex in the world with 10 million patient encounters per year and a 1,345-acre campus (50 million square feet of developed facilities)InFoods® Diagnostic...
LoRa Alliance® to Show How to Achieve Operational Excellence for Smart Buildings at Intelligent Building Systems (IBS) Paris 2019
September 23, 2019 05:00 ET
|
LoRa Alliance
PARIS, Sept. 23, 2019 (GLOBE NEWSWIRE) -- The LoRa Alliance®, the global association of companies backing the open LoRaWAN® standard for the Internet of Things (IoT) low-power wide-area networks...
Biomerica Announces Fiscal Year End 2019 Financial Results
August 30, 2019 08:30 ET
|
Biomerica, Inc.
IRVINE, Calif., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today reported net sales for the fiscal year 2019 were $5,200,682...
Biomerica Announces Notice of Allowance for New U.S. Patent Application Covering Diagnostic Guided Therapy for Irritable Bowel Syndrome (IBS)
April 08, 2019 08:19 ET
|
Biomerica, Inc.
IRVINE, Calif., April 08, 2019 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for...
Why IBS Affects Women Differently: A Capital Digestive Care GI Explains
February 26, 2019 08:24 ET
|
Capital Digestive Care
Silver Spring, MD, Feb. 26, 2019 (GLOBE NEWSWIRE) -- By Leigh Lurie, MD IBS (irritable bowel syndrome) affects about 10% of the global population, making it the most common GI disorder in the...
Why You Could Have Celiac Disease Without Knowing It
September 12, 2018 12:49 ET
|
Capital Digestive Care
Rockville, MD, Sept. 12, 2018 (GLOBE NEWSWIRE) -- By Brian Ciampa, MD Celiac disease is an autoimmune disorder affecting at least three million Americans, but it can be a difficult illness to pin...
RedHill Biopharma Announces Positive End-of-Phase II Meeting with FDA on BEKINDA® for IBS-D
September 12, 2018 07:00 ET
|
RedHill Biopharma Ltd.
The positive Type B meeting with the FDA followed a successful Phase II study of BEKINDA® for diarrhea-predominant irritable bowel syndrome (IBS-D), one of the most common gastrointestinal disorders ...
AXIM® Biotechnologies to Present at BIT’s 16th Annual Congress of International Drug Discovery Science and Technology
August 15, 2018 09:00 ET
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, Aug. 15, 2018 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC: AXIM), a world leader in cannabinoid research and development, today announced that the Company will be...
Biomerica Receives Notice of Allowance for Irritable Bowel Syndrome (IBS) Test Panel and Methods in Korea
August 02, 2018 08:19 ET
|
Biomerica, Inc.
IRVINE, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq:BMRA) announced today that the Korean Intellectual Property Office (KIPO) has issued a Notice of Allowance for a patent...